N-Butyrylphenylalanine | 39895-43-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Butyrylphenylalanine
• 英文别名: butyryl phenylalanine；N-butyryl-phenylalanine；N-Butyryl-phenylalanin；phenylalanine butyramide；n-Butyryl-DL-phenylalanin；2-(Butanoylamino)-3-phenylpropanoic acid
• CAS: 39895-43-7
• 化学式: C₁₃H₁₇NO₃
• mdl: MFCD09806513
• 分子量: 235.283
• InChiKey: POWFRKKVHBUFNI-UHFFFAOYSA-N

物化性质

• 沸点：
  465.4±38.0 °C(Predicted)
• 密度：
  1.143±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.384
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  DL-苯丙氨酸 、 丁酰氯 在 sodium hydroxide 作用下， 以 水 、 丙酮 为溶剂， 以72.2%的产率得到N-Butyrylphenylalanine
  参考文献：
  名称：

  N-酰基氨基酸增强大鼠氨苄青霉素钠的直肠吸收。

  摘要：

  用大鼠直肠环技术研究了氨基酸的N-酰基衍生物对氨苄青霉素钠的直肠吸收的促进作用。在酰基部分具有较长碳链的N-酰基衍生物显示出更大的促进效力。当在相同碳原子长度的酰基部分上比较时，苯基甘氨酸和苯丙氨酸的N-酰基衍生物的促进能力大于甘氨酸和丙氨酸衍生物的促进能力。N-酰基氨基酸的促进作用不受N-乙基马来酰亚胺或哇巴因的存在的影响。在直肠环中存在氯化钙的情况下，N-酰基氨基酸的促进能力受到抑制。讨论了N-酰基氨基酸的钙离子螯合能力对其促进功效的贡献。

  DOI：

  10.1002/jps.2600760703

文献信息

• Compositions for controlled delivery of pharmaceutically active compounds
  申请人：Murthy V.S.N. Yerramilli

  公开号：US20060093632A1

  公开（公告）日：2006-05-04

  The invention relates to pharmaceutical compositions that provide sustained-release of a pharmaceutically active compound and to methods of treating or preventing a condition in an animal by administering the pharmaceutical compositions to the animal by injection. When the pharmaceutical compositions are administered to an animal by injection, they form a drug depot that releases the pharmaceutically active compound over time. The pharmaceutical compositions can also be administered orally.

  该发明涉及提供药物组合物，该药物组合物提供药效活性化合物的持续释放，并且通过注射将药物组合物给动物以治疗或预防动物的某种疾病的方法。当将药物组合物通过注射给动物时，它们形成一个药物库，随着时间释放药效活性化合物。这些药物组合物也可以通过口服给予。
• FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY
  申请人：Berni Canani Roberto

  公开号：US20110098319A1

  公开（公告）日：2011-04-28

  The invention relates to novel derivatives of short-chain fatty acids, in particular derivatives of butyric acid, useful for all the known clinical applications of the latter, which show physicochemical characteristics suitable for an easy oral administration, being devoid of the unpleasant organoleptic properties that characterize butyrate. The new compounds are amide derivatives which can be synthesized by reaction of the corresponding fatty acid halide with a naturally occurring amino acid, phenylalanine or a suitable derivative thereof, and which are in a poorly hygroscopic, easily weighable form, stable to acids and alkalis and able to release the acid at the small and large bowel level in a constant manner over time. They do not have disagreeable odors and are practically tasteless, thus allowing the manufacture of preparations for oral administration also suitable for the therapy of chronic diseases and in the pediatric field.

  本发明涉及一种新型的短链脂肪酸衍生物，特别是丁酸衍生物，适用于后者的所有已知临床应用，具有适合易于口服的物理化学特性，不具有表征丁酸的不愉快的感官特性。新的化合物是酰胺衍生物，可以通过相应的脂肪酸卤化物与天然存在的氨基酸苯丙氨酸或其适当衍生物反应合成，并且以不易吸湿，易于称重的形式存在，对酸和碱稳定，并且能够在时间上以恒定的方式释放酸到小肠和大肠水平。它们没有不愉快的气味，几乎没有味道，因此可以制备适合于口服治疗慢性疾病和儿科领域的制剂。
• AKT PROTEIN KINASE INHIBITORS
  申请人：Array BioPharma, Inc.

  公开号：US20140148436A1

  公开（公告）日：2014-05-29

  The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

  本发明提供了化合物，包括已分离的对映体、非对映异构体、溶剂化物和药学上可接受的盐，其化学式为A-L-CR，其中CR是一个环状核心基团，L是一个连接基团，A如本文所定义。本发明还提供了使用该化合物作为AKT蛋白激酶抑制剂和用于治疗高增殖性疾病，如癌症的方法。
• Composition containing a penem or carbapenem antibiotic
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0178911A2

  公开（公告）日：1986-04-23

  57 Administration of an N-acylated amino acid (ornithine, lysine, phenylglycine or phenylalanine) in association with a penem or carbapenem antibiotic relieves or eliminates the renal problems associated with administration of the antibiotic alone. The amino acid and antibiotic may be formulated together as a composition or administered separately, either simultaneously or sequentially. A pharmaceutical composition may be prepared simply by mixing the two components.

  57 将 N-酰化氨基酸（鸟氨酸、赖氨酸、苯甘氨酸或苯丙氨酸）与培南类或碳青霉烯类抗生素联合给药，可缓解或消除与单独给药抗生素相关的肾脏问题。 氨基酸和抗生素可一起配制成组合物，也可同时或依次单独给药。 只需将两种成分混合即可制备成药物组合物。
• SYNTHESIS AND USES OF PEPTIDE BORATE ESTER COMPOUND
  申请人：Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.

  公开号：EP3805237A1

  公开（公告）日：2021-04-14

  Provided are a peptide borate ester compound or a pharmaceutically acceptable salt thereof, a preparation method therefor, and pharmaceutical use thereof. The peptide borate ester compound or pharmaceutically acceptable salt thereof has a structure as shown in Formula (I), and is useful in the preparation of proteasome inhibitors to treat solid tumors and hematoma.

  本文提供了一种肽硼酸酯化合物或其药学上可接受的盐、其制备方法及其药物用途。肽硼酸酯化合物或其药学上可接受的盐具有如式（I）所示的结构，可用于制备蛋白酶体抑制剂以治疗实体瘤和血肿。